Who are Giapreza's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Angiotensin Ii, lidocaine + epinephrine 1:100,000, Buffered Articaine Hydrochloride + Epinephrine, Articaine Hydrochloride + Epinephrine, Xylocaine with Epinephrine, Levobupivacaine with epinephrine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/angiotensin-ii.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Giapreza — Competitive Intelligence Brief

Giapreza (ANGIOTENSIN II) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vasoconstrictor [EPC]. Area: Hematology.

marketed Vasoconstrictor [EPC] Type-2 angiotensin II receptor, Type-1 angiotensin II receptor, Type-1 angiotensin II receptor Hematology Recombinant protein Live · refreshed every 30 min

Target snapshot

Giapreza (ANGIOTENSIN II) — La Jolla Pharma. Giapreza works by mimicking the action of angiotensin II to constrict blood vessels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Giapreza TARGET	ANGIOTENSIN II	La Jolla Pharma	marketed	Vasoconstrictor [EPC]	Type-2 angiotensin II receptor, Type-1 angiotensin II receptor, Type-1 angiotensin II receptor	2017-01-01
Angiotensin Ii	ANGIOTENSIN	La Jolla Pharma	marketed	Vasoconstrictor [EPC]		2025-01-01
lidocaine + epinephrine 1:100,000	lidocaine + epinephrine 1:100,000	Weill Medical College of Cornell University	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels (lidocaine); alpha-1 and beta-1 adrenergic receptors (epinephrine)
Buffered Articaine Hydrochloride + Epinephrine	Buffered Articaine Hydrochloride + Epinephrine	Ohio State University	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (epinephrine component)
Articaine Hydrochloride + Epinephrine	Articaine Hydrochloride + Epinephrine	Ankara Yildirim Beyazıt University	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (epinephrine component)
Xylocaine with Epinephrine	Xylocaine with Epinephrine	Vrije Universiteit Brussel	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-1 adrenergic receptors
Levobupivacaine with epinephrine	Levobupivacaine with epinephrine	Pontificia Universidad Catolica de Chile	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (epinephrine component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vasoconstrictor [EPC] class)

La Jolla Pharma · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Giapreza — Competitive Intelligence Brief. https://druglandscape.com/ci/angiotensin-ii. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab